ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational...

Full description

Saved in:

Bibliographic Details
Published in:	Oncogene Vol. 37; no. 33; pp. 4611 - 4625
Main Authors:	Berns, Katrien, Caumanns, Joseph J., Hijmans, E. Marielle, Gennissen, Annemiek M. C., Severson, Tesa M., Evers, Bastiaan, Wisman, G. Bea A., Jan Meersma, Gert, Lieftink, Cor, Beijersbergen, Roderick L., Itamochi, Hiroaki, van der Zee, Ate G. J., de Jong, Steven, Bernards, René
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.08.2018 Nature Publishing Group
Subjects:	13/1 13/106 13/109 13/51 13/89 14/63 38/23 38/47 45/15 631/154/555 631/67/1517/1709 96/44 Apoptosis Cancer Cancer cells Carcinoma Care and treatment Cell Biology Development and progression Disease management Gene mutation Genetic aspects Health aspects Human Genetics Innovations Internal Medicine Lethality Medical research Medical schools Medicine Medicine & Public Health Molecular targeted therapy Mutation Oncology Ovarian cancer Ovarian carcinoma Patients Proteins Tumor cell lines Xenografts
ISSN:	0950-9232, 1476-5594, 1476-5594
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!